Table 1.
Tissue masses
| Sed CR | Run CR | Placebo post-WL | Mifepristone post-WL | |
|---|---|---|---|---|
| Final body mass | 258 ± 3.80ab | 198 ± 4.00a | 303 ± 19.3b | 277 ± 21.9b |
| Epididymal fat depot | 2.64 ± 0.30a | 0.86 ± 0.09b | 4.48 ± 0.17c | 3.76 ± 0.21c |
| 0.68 ± 0.08a | 0.17 ± 0.02b | 1.36 ± 0.06c | 1.09 ± 0.06d | |
| Perirenal fat depot | 0.42 ± 0.07a | 0.20 ± 0.02b | 0.91 ± 0.04c | 0.64 ± 0.07d |
| 0.11 ± 0.02a | 0.04 ± 0.01b | 0.28 ± 0.02c | 0.17 ± 0.02d | |
| Inguinal fat depot | 1.88 ± 0.22a | 0.30 ± 0.06b | 3.28 ± 0.32c | 2.11 ± 0.20a |
| 0.48 ± 0.05a | 0.06 ± 0.01b | 0.88 ± 0.09c | 0.58 ± 0.05a | |
| Tibialis anterior | 1.97 ± 0.05a | 1.95 ± 0.06a | 1.78 ± 0.02b | 1.79 ± 0.03b |
| 0.51 ± 0.02a | 0.39 ± 0.02b | 0.54 ± 0.01a | 0.50 ± 0.02a | |
| Plantaris | 0.96 ± 0.04a | 0.90 ± 0.03ab | 0.86 ± 0.02b | 0.90 ± 0.02ab |
| 0.25 ± 0.01a | 0.18 ± 0.01b | 0.26 ± 0.01a | 0.25 ± 0.01a | |
| Soleus | 0.45 ± 0.02a | 0.54 ± 0.02b | 0.45 ± 0.01a | 0.45 ± 0.02a |
| 0.11 ± 0.01a | 0.11 ± 0.01a | 0.14 ± 0.01b | 0.13 ± 0.01ab | |
| Gastrocnemius | 5.23 ± 0.13a | 4.96 ± 0.12ab | 4.67 ± 0.11b | 4.86 ± 0.11ab |
| 1.35 ± 0.04a | 1.00 ± 0.04b | 1.42 ± 0.05a | 1.35 ± 0.05a | |
| Liver | 30.2 ± 0.36a | 30.7 ± 1.48a | 35.9 ± 1.25b | 37.9 ± 1.27b |
| 7.78 ± 0.10a | 6.19 ± 0.30a | 10.9 ± 0.53b | 10.5 ± 0.43b | |
| Adrenals | 79.1 ± 3.67a | 102.3 ± 5.29b | 76.4 ± 2.42a | 78.3 ± 2.57a |
| 20.6 ± 1.01a | 20.5 ± 1.21a | 22.1 ± 1.21a | 21.5 ± 0.40a |
All data are means ± SE; n = 8–10 for adipose tissue, skeletal muscle, and liver; n = 3–4 for adrenals. Final fasted body mass (g). Relative (g/kg body mass) and absolute (g) tissue masses, respectively, for adipose tissue, skeletal muscle, and liver. Relative (mg/kg body mass) and absolute (mg) adrenal mass.
Sed, sedentary; CR, caloric restriction; post-wheel lock (post-WL).
Different letter indicates a significant difference (P < 0.05). All data were analyzed by 1-way ANOVA and Tukey's post hoc test.